°ÄÃÅÐÂÆÏ

µ±Ç°Î»Öãº ÍøÕ¾Ê×Ò³ > ÐÂÎŶ¯Ì¬ > ÕýÎÄ

ÐÂÎŶ¯Ì¬
ÐÂÎŶ¯Ì¬
°ÄÃÅÐÂÆÏ½üÆÚÖØµã¿ÆÑÐËÙÀÀ
À´Ô´£º¡°ÈÊÐÄ¡±Í¨Ñ¶Éç¡¡µÚÒ»¸½ÊôÒ½Ôº¡¡»ù´¡Ò½Ñ§Ôº¡¡Ò©Ñ§Ôº    ÈÕÆÚ£º2024-06-04     ä¯ÀÀ´ÎÊý£º
¡¡¡¡½üÆÚ£¬°ÄÃÅÐÂÆÏÈ¡µÃ¶àÏî¿ÆÑÐÐÂÍ»ÆÆ£¬Ë¶¹ûÀÛÀÛ£¬³É¾ÍÆÄ·á¡£ÌØÑ¡²¿·ÖÖØµã¿ÆÑгɹûËÙÀÀ»Ø¹Ë¡£
°ÄÃÅÐÂÆÏÒ½¹¤Ð­×÷ÍŶÓÔÚÈ«ÉíÂé×íÒ©Îï¼õ¶¾ÔöЧ·½ÃæÈ¡µÃÖØÒª½øÕ¹
¡¡
¡¡¡¡½üÈÕ£¬°ÄÃÅÐÂÆÏÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺ²©Ê¿ÉúÕÅ˸ΪµÚÒ»×÷Õߣ¬ÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺÎâµÀ³Î½ÌÊں͵ÚÒ»¸½ÊôÒ½ÔºÂé×íÊÖÊõ²¿¸±Ö÷ÈθßΡ¸±Ö÷ÈÎҽʦΪ¹²Í¬Í¨Ñ¶×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶¾Û¼¯Ìå¡·£¨Aggregate, IF=18.8£©ÉÏÔÚÏß·¢±íÒÔÌâΪ¡¶³¬ÉùÁªºÏѪÄÔÆÁÕϰÐÏò·Ö×ÓµÝËÍËĺÏÒ»·Ö×Ó¾Û¼¯ÌåÈëÄÔͨ¹ýÒì±û·Ó-ÒÀÍÐßäõ¥Ð­Í¬ÒÖÖÆGABAÊÜÌåÀ´ÔöÇ¿Âé×íЧ¹û²¢½µµÍ¶¾ÐÔ¡·µÄÑо¿ÂÛÎÄ¡£¸Ã¹¤×÷µÃµ½Á˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢ÉÂÎ÷Ê¡¡°¸ß²ã´ÎÈ˲ÅרÏîÖ§³Ö¼Æ»®¡±ÇàÄê°Î¼âÈ˲ÅÏîÄ¿µÄ×ÊÖú¡£°ÄÃÅÐÂÆÏ·ÖÎö²âÊÔÖÐÐĺÍÉúÎïҽѧʵÑéÖÐÐÄΪ±¾¹¤×÷ÌṩÁË´óÁ¿Ñо¿Ö§³Ö¡£
µÚÒ»¸½ÊôÒ½ÔººÎÍúæç¿ÆÑÐÍŶÓÔÚÖ×ÁöÃâÒßÖÎÁÆÎ¢µ°°×Ò©ÎïÉè¼Æ·½Ãæ±³¿¿±³·¢±íÑо¿³É¹û
¡¡¡¡°ÄÃÅÐÂÆÏµÚÒ»¸½ÊôÒ½ÔººÎÍúæçÑо¿Ô±ÎªÎÄÕÂͨѶ×÷Õߣ¬Ö×ÁöÄڿƽ¯°®Ãñ²©Ê¿Îª±¾ÎĵÚÒ»×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶ACS Nano¡·£¨IF=17.1£©ÉÏ·¢±íÌâΪ¡°Advancing the boundaries of immunotherapy in lung adenocarcinoma with idiopathic pulmonary fibrosis by a biomimetic proteinoid enabling selective endocytosis¡±µÄ¿ÆÑÐÂÛÎÄ¡£
µÚÒ»¸½ÊôÒ½ÔºÖ×Áö·ÅÁÆ¿ÆÕÔ¶«Àû½ÌÊÚÍŶÓÔÚ¡¶ÁøÒ¶µ¶¡·Õý¿¯·¢±íÖØÒªÑо¿ÆÀÊöÎÄÕÂ
¡¡¡¡µÚÒ»×÷ÕßÕÔ¶«Àû½ÌÊÚ¡¢Í¨Ñ¶×÷Õß·ӽ¿­ÎïÀíʦ£¨¹²Í¬×÷ÕßÀîÒã¸ß¼¶¹¤³Ìʦ¡¢ÇúÒÔÆ½Ö÷ÖÎҽʦºÍºÎ³¿è¡Ö÷ÖÎҽʦ£©ÔÚ¡¶ÁøÒ¶µ¶¡·£¨IF=168.9£©ÉϵÄcorrespondenceרÀ¸ÉÏ·¢±íÒÔ¡°Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial£¨SIBÈéÏÙ·ÅÉäÖÎÁÆÃæÁÙµÄÌôÕ½£ºIMPORT HIGHÊÔÑ飩¡±ÎªÌâµÄÎÄÕ¡£
»ù´¡Ò½Ñ§ÔºÍŶÓÑо¿·¢±íÖáÍ»ÄÒÅÝɸѡлúÖÆ
¡¡¡¡°ÄÃÅÐÂÆÏ»ù´¡Ò½Ñ§ÔºÑîÌÊÚ£¬ÍŶӳÉÔ±²©Ê¿ºóº«ÔÀ¡¢ÁõÕÜ£¬²©Ê¿ÉúÀîÃô£¬Ñо¿ÉúÕÔ±ùÇå¡¢ÁõÑà¡¢Íõ»Û³¬£¬ÔÚ¡¶ÃÀ¹ú¿ÆÑ§ÔºÔº¿¯¡·(PNAS)ÉÏ·¢±íÌâΪ¡¶MARK2Á×ËữKIF13AµÄ14-3-3½áºÏλµãµ÷¿Ø×ªÌúµ°°×ÊÜÌåÄÒÅÝÔÚÊ÷Í»Éϵļ«»¯×ªÔË¡·£¨MARK2 phosphorylates KIF13A at a 14-3-3 binding site to polarize vesicular transport of transferrin receptor within dendrites£©µÄ¿ÆÑÐÎÄÕ¡£¸ÃÑо¿ÎªÖáÍ»ÎïÖʵÄÑ¡ÔñÐÔתÔËÌṩÁËÒ»¸öеÄÊӽǣ¬¼´ÄÒÅݵļ«ÐÔתÔË¿ÉÄÜÓëÖáÍ»ÆðÊ¼ÇøÓò¸»¼¯µÄµ°°×¼¤Ã¸µ÷¿ØÏà¹Ø¡£
ҩѧԺÕÅÑåÃñ½ÌÊÚÁªºÏ»¯¹¤Ñ§Ôº³ÂöνÌÊÚ¡¢Äܶ¯Ñ§ÔºÁõº£ºþ½ÌÊÚ
¹¹½¨»ùÓÚÉúÀíÏìÓ¦¼°µ÷¿ØÐÍÄÉÃ×½ð´ØµÄ¾«×¼¿ÉÊÓ¶ñÐÔÖ×ÁöÖÎÁÆ
¡¡¡¡°ÄÃÅÐÂÆÏҩѧԺÕÅÑåÃñ½ÌÊÚ¡¢»¯¹¤Ñ§Ôº³ÂöνÌÊÚ¡¢Äܶ¯Ñ§ÔºÁõº£ºþ½ÌÊÚΪÂÛÎĵÄͨѶ×÷Õߣ¬²©Ê¿ÉúÁõ·ã¡¢ÑîÌì·ãºÍ³£Ð¡ÎÀΪ¹²Í¬µÚÒ»×÷Õߣ¬ÔÚ¡¶¹ú¼Ò¿ÆÑ§ÆÀÂÛ¡·£¨National Science Review£©·¢±íÌâΪ¡°Intelligent gold nanocluster for effective treatment of malignant tumor via tumor-specific photothermal-chemodynamic therapy with AIE guidance¡±µÄ¿ÆÑÐÂÛÎÄ¡£¸ÃÂÛÎĵõ½Á˹ú¼Ò¸ß²ã´ÎÈ˲ÅÌØÊâÖ§³Ö¼Æ»®¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢ÉÂÎ÷Ê¡×ÔÈ»¿ÆÑ§»ù½ð¡¢°ÄÃÅÐÂÆÏ¡°ÇàÄê°Î¼âÈ˲ÅÖ§³Ö¼Æ»®¡±µÈÏîÄ¿µÄ´óÁ¦Ö§³Ö¡£
  • ½»´óÖ÷Ò³
  • ѧ²¿ÐÅÏä
  • ˼ԴBBS
  • ͼÊé¹Ý
  • ˼ԴÓʼþ
  • ÐÅÏ¢ÃÅ»§
  • ½ÌʦÖ÷Ò³

µØÖ·£ºÉÂÎ÷Ê¡Î÷°²ÊÐÑãËþÎ÷·76ºÅ£¬Óʱࣺ710061

°æÈ¨ËùÓУº°ÄÃÅÐÂÆÏ

·ÃÎÊÁ¿£º

΢ÐÅÆ½Ì¨

°ÄÃÅÐÂÆÏµç×ÓÓÎÏ·Íø³©Íæ°ÄÃÅÐÂÆÏµç×ÓÓÎϷƽ̨¾¡ÏíÓéÀÖÊ¢Ñç